Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine

• DOI: 10.1111/ene.16106
• Publication Date: 2023-10-17T14:25:49Z
• Authors: Simone de Vries L...; Britt W. H. van d...; Irene de Boer; Erik W. van Zwet; Antoinette Maasse...; Gisela M. Terwindt
• Keywords: Depression

Abstract Background and purpose The aim was to evaluate the effect of anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies on depressive symptoms in subjects with migraine determine whether predict treatment response. Methods Patients treated erenumab fremanezumab at Leiden Headache Centre completed daily E‐headache diaries. A control group included. Depressive were assessed using Hospital Anxiety Depression Scale (HADS) Center for Epidemiological Studies (CES‐D) questionnaires baseline (T0) after 3 months (T1). First, reduction HADS‐D CES‐D scores assessed, depression as dependent variable monthly days (MMD) anti‐CGRP medication independent variables. Second, a predictor response investigated, absolute MMD age, gender, MMD, active depression, impact, stress locus Results In total, n = 108 patients erenumab, 90 68 without treatment. Treatment positively associated ( β 1.65, p 0.01) compared control, reduction. However, same not found 2.15, 0.21). Active predicted poorer 0.02) but 0.09). Conclusion Anti‐CGRP monoclonals lead improvement individuals migraine, may fremanezumab.